Guillain‑Barré syndrome following BNT162b2 COVID‑19 vaccine

Italy, 25 July 2021, Trimboli et al, Neurological Sciences


We describe a case of GBS after receiving the second dose of COVID-19 vaccine [BNT162b2—Pfizer®]. A 25-year-old woman without other comorbidities presented to our department on February 26th 2021 with a history of progressive lower limbs weakness and paresthesias for 4 days. She reported difficulty in walking and climbing stairs associated to paresthesias and numbness in the anterolateral region of the right thigh. The patient had received the first dose of COVID-19 vaccine [BNT162b2—Pfizer®] on January 19th 2021 and the second dose on February 18th 2021. No infectious illness or other events were experienced in the weeks prior to the onset of symptoms.

Download PDF

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s